These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23429762)

  • 61. The interactive effects of ketamine and magnesium upon depressive-like pathology.
    Razmjou S; Litteljohn D; Rudyk C; Syed S; Clarke M; Pentz R; Dwyer Z; Hayley S
    Neuropsychiatr Dis Treat; 2016; 12():2049-56. PubMed ID: 27660449
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis.
    Yan T; Wang L; Kuang W; Xu J; Li S; Chen J; Yang Y
    Asia Pac Psychiatry; 2014 Sep; 6(3):241-51. PubMed ID: 25231750
    [TBL] [Abstract][Full Text] [Related]  

  • 63. No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients.
    Yoshimura R; Kishi T; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Hayashi K; Iwata N; Nakamura J
    Clin Psychopharmacol Neurosci; 2012 Apr; 10(1):49-53. PubMed ID: 23429762
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serum brain-derived neurotrophic factor, Val66Met polymorphism and open-label SSRI treatment response in Major Depressive Disorder.
    Smit AJT; Wu GWY; Rampersaud R; Reus VI; Wolkowitz OM; Mellon SH
    Psychoneuroendocrinology; 2024 Jul; 165():107045. PubMed ID: 38636352
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients.
    Colle R; Gressier F; Verstuyft C; Deflesselle E; Lépine JP; Ferreri F; Hardy P; Guilloux JP; Petit AC; Fève B; Falissard B; Becquemont L; Corruble E
    J Affect Disord; 2015 Apr; 175():233-40. PubMed ID: 25658497
    [TBL] [Abstract][Full Text] [Related]  

  • 66. No association between BDNF Val66Met polymorphism and treatment response in obsessive-compulsive disorder in the Japanese population.
    Umehara H; Numata S; Kinoshita M; Watanabe S; Nakaaki S; Sumitani S; Ohmori T
    Neuropsychiatr Dis Treat; 2016; 12():611-5. PubMed ID: 27042072
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.
    Yoshimura R; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Hayashi K; Atake K; Tomita M; Nakamura J
    Hum Psychopharmacol; 2012 Jan; 27(1):33-8. PubMed ID: 22213405
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients.
    Yoshimura R; Kishi T; Suzuki A; Umene-Nakano W; Ikenouchi-Sugita A; Hori H; Otani K; Iwata N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1022-5. PubMed ID: 21338649
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics.
    González-Pinto A; Mosquera F; Palomino A; Alberich S; Gutiérrez A; Haidar K; Vega P; Barbeito S; Ortiz A; Matute C
    Int Clin Psychopharmacol; 2010 Jul; 25(4):241-5. PubMed ID: 20568658
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics.
    Rizos EN; Papadopoulou A; Laskos E; Michalopoulou PG; Kastania A; Vasilopoulos D; Katsafouros K; Lykouras L
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):251-5. PubMed ID: 20218789
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder.
    Zou YF; Ye DQ; Feng XL; Su H; Pan FM; Liao FF
    Eur Neuropsychopharmacol; 2010 Aug; 20(8):535-44. PubMed ID: 20167454
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression.
    Yoshimura R; Ikenouchi-Sugita A; Hori H; Umene-Nakano W; Katsuki A; Hayashi K; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):308-12. PubMed ID: 20005280
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
    Nelson JC; Papakostas GI
    Am J Psychiatry; 2009 Sep; 166(9):980-91. PubMed ID: 19687129
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.
    Crossley NA; Bauer M
    J Clin Psychiatry; 2007 Jun; 68(6):935-40. PubMed ID: 17592920
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.